In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Pharmaceuticals Ltd.

http://www1.actelion.com/en/index.page

Latest From Actelion Pharmaceuticals Ltd.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Drug Review

Coronavirus Notebook: EMA Hones In On COVID-19 Activities, Russia’s Sputnik V launches in India

A new study shows that the immune response to Pfizer/BioNTech’s Comirnaty in elderly people is 3.5-fold greater when the second dose is given after 12 weeks rather than three. The WHO has OKd the emergency use of a Chinese vaccine.

Europe International

Lupin Pursues India Approval For Lucentis Biosimilar, COVID-19 Opportunities

A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.

Strategy Sales & Earnings

More Competition Coming To Cushing's Market

Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space

Rare Diseases Strategy
See All

Company Information

  • Other Names / Subsidiaries
    • Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
    • CoTherix, Inc
UsernamePublicRestriction

Register